Gilead Sciences is reporting some preliminary results from the use of its antiviral drug remdesivir in treating patients with COVID-19. More than half the patients in the study experienced side effect from the drug, ranging from a rash and diarrhea to acute kidney injury. | Poal: Say what you want.

Welcome • User Guide
ToS • Privacy • Canary
Donate • Bugs • License

©2025 Poal.co

1.2K

•

Gilead Sciences is reporting some preliminary results from the use of its antiviral drug remdesivir in treating patients with COVID-19. More than half the patients in the study experienced side effect from the drug, ranging from a rash and diarrhea to acute kidney injury. (archive.md)

(post is archived)